Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers

Table 1

Distribution of ER/PR/HER2 and grade that constitute the surrogate molecular classification of combined stages 1–4 breast cancer from the California Cancer Registry 2000–2010.

		Grade 1	Grade 2	Grade 3	Grade 4	Not stated	Total
Luminal A	ER+/PR+/HER2−	23,904 (38.4%)	38,340 (61.6%)				62,244
	ER+/PR−/HER2−	3,344 (36.7%)	5,765 (63.3%)				9,109
	ER−/PR+/HER2−	117 (27.5%)	308 (72.5%)				425
Luminal B, HER2 negative	ER+/PR+/HER2−			13,891 (96.0%)	584 (4.0%)		14,475
	ER+/PR−/HER2−			3,694 (95.5%)	175 (4.5%)		3,869
	ER−/PR+/HER2−			637 (95.5%)	30 (4.2%)		667
Luminal B, HER2 positive	ER+/PR+/HER2+	1,708 (12.4%)	5,803 (42.3%)	5,285 (38.5%)	256 (1.9%)	667 (4.9%)	13,719
	ER+/PR−/HER2+	331 (7.0%)	1,789 (37.8%)	2,223 (46.9%)	108 (2.3%)	284 (6.0%)	4,735
	ER−/PR+/HER2+	16 (2.8%)	143 (25.4%)	345 (61.3%)	29 (5.2%)	30 (5.3%)	563
Triple negative	ER−/PR−/HER2−	508 (2.7%)	3,045 (16.3%)	13,643 (72.9%)	697 (3.7%)	831 (4.4%)	18,724
HER2 overexpressing	ER−/PR−/HER2+	159 (1.6%)	2,002 (20.4%)	6,640 (67.8%)	374 (3.8%)	617 (6.3%)	9,792
Total		30,087 (21.8%)	57,195 (41.3%)	46,358 (33.5%)	2,253 (1.6%)	2,429 (1.8%)	138,322